Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept Reports Third Quarter 2018 Financial Results
Company to host conference call at 4:30 p.m. Eastern time today SAN DIEGO , Nov. 13, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer
View HTML
Toggle Summary Biocept to Release Third Quarter 2018 Financial Results and Host Investor Conference Call on November 13, 2018
SAN DIEGO , Nov. 6, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that it will release financial
View HTML
Toggle Summary Biocept Announces New Executive Hires to its Sales and Marketing Organization
Appoints Scott Nicholson as Vice President of National Sales - US; Cory Dunn as Vice President of Marketing SAN DIEGO , Nov. 5, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable
View HTML
Toggle Summary Biocept to Present at the Dawson James Securities Small Cap Growth Conference on October 30
SAN DIEGO , Oct. 23, 2018 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W.
View HTML
Toggle Summary Biocept Obtains Japanese Patent for its Target Selector Oncogene Mutation Enrichment and Detection Platform
Expands intellectual property to 30 issued patents globally for highly sensitive methods of detecting cancer biomarkers SAN DIEGO , Oct. 18, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically
View HTML
Toggle Summary Biocept to Present at The MicroCap Conference in New York on October 2
SAN DIEGO , Sept. 25, 2018 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael
View HTML
Toggle Summary Biocept Awarded Patent in Hong Kong for its Target Selector Platform Using Antibodies and a Microchannel to Perform Liquid Biopsy
Expands the Company's global patent estate for the capture and detection of rare cells of interest, including CTCs shed by solid tumors, in blood and other biofluids SAN DIEGO , Sept. 24, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests
View HTML
Toggle Summary Biocept Announces Pricing of $2.5 Million Registered Direct Offering Priced at Market
SAN DIEGO , Sept. 21, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced it has
View HTML
Toggle Summary Biocept Names Edwin C. Hendrick as Senior Vice President, Chief Commercial Officer
SAN DIEGO , Sept. 10, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the appointment of Edwin C.
View HTML
Toggle Summary Biocept's Target Selector Platform Featured in Two Poster Presentations at the IASLC 19th World Conference on Lung Cancer
Clinical study data highlight the ability of Biocept's proprietary liquid biopsy technology to detect and monitor actionable biomarkers and circulating tumor cell counts in the blood and in cerebrospinal fluid of non-small cell lung cancer patients SAN DIEGO , Sept.
View HTML